JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14
JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
Share
Why It Matters
A big bank analyst says Integra Lifesciences looks less attractive now. They lowered their price target, which means they think the stock might go lower.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.